Gelteq Limited Ordinary Shares (GELS)
Automate Your Wheel Strategy on GELS
With Tiblio's Option Bot, you can configure your own wheel strategy including GELS - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol GELS
- Rev/Share 0.0
- Book/Share 0.0
- PB 0.0
- Debt/Equity 0.2668
- CurrentRatio 0.2675
- ROIC -0.2741
- MktCap 14242660.6063
- FreeCF/Share 0.0
- PFCF -2.3107
- PE 0.0
- Debt/Assets 0.1964
- DivYield 0
- ROE -0.4299
- Rating D+
- Score 1
- Recommendation Strong Sell
- P/E Score 1
- DCF Score 1
- P/B Score 1
- D/E Score 2
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| No ratings available. | |||||||
News
Gelteq Announces Positive Preclinical Results Showing Increased Medicinal Cannabinoid Absorption Using Its Oral Gel Delivery Platform
Published: January 13, 2026 by: GlobeNewsWire
Sentiment: Neutral
MELBOURNE, Australia, Jan. 13, 2026 (GLOBE NEWSWIRE) -- Gelteq Limited (“Gelteq” or the “Company”), a clinical and science-based developer of advanced gel-based oral delivery systems, today announced positive results from a recently completed preclinical study which evaluated medicinal cannabinoids delivery through the Company's proprietary oral gel platform. The findings demonstrate that Gelteq's platform significantly enhances the absorption and bioavailability of cannabidiol (“CBD”) compared to an existing FDA approved oil-based product. The preliminary results reinforces our platform's potential to change how medicinal cannabis is delivered and experienced by patients.
Read More
Gelteq Furthers Asia Presence Through Partnership with Hong Kong Flag Football Program
Published: December 16, 2025 by: GlobeNewsWire
Sentiment: Neutral
Collaboration Combines Growing International Interest in Gelteq's Sports Science Technology with Rising Interest in Flag Football Ahead of 2028 Summer Olympic Games Debut in Los Angeles Collaboration Combines Growing International Interest in Gelteq's Sports Science Technology with Rising Interest in Flag Football Ahead of 2028 Summer Olympic Games Debut in Los Angeles
Read More
Gelteq Signs Three Year Sales Agreement with Shenzhen Mana Health Management Co. Strengthening Gelteq's Nutritional Product Expansion into China
Published: December 09, 2025 by: GlobeNewsWire
Sentiment: Neutral
Agreement includes minimum annual order commitments totalling approximately USD $1.3 million Agreement includes minimum annual order commitments totalling approximately USD $1.3 million
Read More
Gelteq Preclinical Study Demonstrates Enhanced Oral Delivery of Oil-Soluble and Poorly Soluble Drugs Using Its Gel-Based Platform
Published: December 05, 2025 by: GlobeNewsWire
Sentiment: Neutral
MELBOURNE, Australia, Dec. 05, 2025 (GLOBE NEWSWIRE) -- Gelteq Limited (“Gelteq” or the “Company”), a clinical and science-based developer of advanced gel-based oral delivery systems, today announced preclinical findings demonstrating the effectiveness, flexibility, and safety profile of its proprietary gel platform. The results address a major challenge in pharmaceutical development and demonstrate that Gelteq's technology can enhance the oral delivery of oil-soluble and poorly soluble drugs.
Read More
Gelteq Announces Commencement of Preclinical Trial for Novel Gel-Based Antihistamine Formulation Targeting Allergy Market
Published: September 05, 2025 by: GlobeNewsWire
Sentiment: Neutral
MELBOURNE, Australia, Sept. 05, 2025 (GLOBE NEWSWIRE) -- Gelteq Limited (“Gelteq” or the “Company”), a clinical and science-based company specialising in gel-based oral delivery solutions, today announced plans to commence a preclinical bioequivalence study in September 2025 to evaluate its novel gel-based formulation of a widely used antihistamine for allergy treatment.
Read More
Healthy Extracts Reports Record Q2 2025 Net Revenue, Driving Positive EPS and EBITDA; Increases 2025 Net Revenue Guidance by 50%
Published: August 13, 2025 by: Accesswire
Sentiment: Neutral
Net Revenue Outlook for 2025 Increased from $4.2 Million+ to $6.3 Million+, Representing Growth of 102%+, Based on Recent Transformative Merger with Gummy USA LAS VEGAS, NV / ACCESS Newswire / August 13, 2025 / Healthy Extracts Inc. (OTCQB:HYEX), a leader in plant-based nutraceutical innovations, reported results for its second quarter and six months ended June 30, 2025. All comparisons are to the same year-ago period unless otherwise noted.
Read More
Gelteq Announces Agreement with IDT Australia to Secure Dedicated New Product Development and Manufacturing Facilities
Published: July 17, 2025 by: GlobeNewsWire
Sentiment: Neutral
Partnership to support the scale-up and commercialization of Gelteq's proprietary gel-based oral delivery platform Partnership to support the scale-up and commercialization of Gelteq's proprietary gel-based oral delivery platform
Read More
Gelteq's Sportsgel Brand Named Official Sponsor of the Professional Pickleball Tour and League of Australia and New Zealand
Published: February 27, 2025 by: GlobeNewsWire
Sentiment: Neutral
Sportsgel signs first league-wide sports deal to be the official performance gel of the preeminent pickleball tour across the Oceania region Sportsgel signs first league-wide sports deal to be the official performance gel of the preeminent pickleball tour across the Oceania region
Read More
About Gelteq Limited Ordinary Shares (GELS)
- IPO Date 2024-10-29
- Website https://www.gelteq.com
- Industry Drug Manufacturers - Specialty & Generic
- CEO Nathan Jacob Givoni
- Employees 7